Table 5.

Characteristics and outcomes of 10 patients who received CD19 CAR T-cell retreatment of post–CAR T disease progression

		First CAR T-cell therapy										Second CAR T-cell therapy
ID	Disease status at first CAR T-cell therapy	Lympho- depletion	Dose (cells per kg)	Peak expansion (vcn/mL)	CRS maximum grade	ICANS maximum grade	Response to first CAR T-cell therapy	Relapse site/burden	Time from first CAR T to second CAR T (d)	Disease status at second CAR T-cell therapy	Lympho- depletion	Dose (/kg)	Peak CAR T expansion (vcn/mL)	CRS maximum grade	ICANS maximum grade	Response to second CAR T-cell therapy	Post-second CAR T treatment	Living status last contact
MSK7		Morphologic	Cy 3 g/m2	3×106	62 719	1	3	MRD− CR	BM/gross	166	Morphologic	Cy 1.5 g/m2	3×106	13 353	1	No	NR	No	Dead (disease)
MSK9	MRD	Cy 1.5 g/m2	0.4×106	5208	No	No	MRD− CR	BM/MRD	204	MRD	Cy 3 g/m2	3×106	0	1	No	NR	Yes	Dead (disease)
MSK13	Morphologic	Cy 3 g/m2	3×106	2 320 302	3	3	MRD− CR	BM/gross	1041	Morphologic	Flu/Cy	1×106	746	No	No	NR	Yes	Dead (disease)
MSK16	MRD	Cy 3 g/m2	3×106	0	2	2	MRD− CR	EM, BM/gross	104	MRD	Cy 3 g/m2	3×106	0	No	No	MRD− CR	No	Dead (disease)
MSK17	Morphologic	Cy 3 g/m2	3×106	197 262	4	4	MRD− CR	BM/gross	104	Morphologic	Cy 2 g/m2	3×106	200 363	3	5	MRD− CR	No	Dead (TRM)
MSK24	Morphologic	Cy 3 g/m2	1×106	34 183	1	No	MRD+ CR	BM/gross	80	Morphologic	Cy 3 g/m2	1×106	0	1	No	NR	Yes	Dead (unknown)
MSK29	MRD−	Cy 3 g/m2	3×106	26 210	1	2	MRD− CR	BM/gross	1110	Morphologic	Flu/Cy	3×106	35 800	1	1	NR	No	Dead (unknown)
MSK36	MRD	Cy 3 g/m2	3×106	0	No	No	MRD+ CR	BM/gross	343	Morphologic	Flu/Cy	1×106	177 758	1	No	NR	Yes	Alive
MSK44	Morphologic	Flu/Cy	1×106	129 980	1	3	MRD+ CR	EM, BM/gross	451	Morphologic	Cy 3 g/m2	1×106	0	2	No	MRD+ CR	Yes	Alive
MSK56	Morphologic	Flu/Cy	1×106	20 400	2	0	MRD+ CR	BM/MRD	164	MRD	Flu/Cy	1×106	18 900	2	No	MRD− CR	Yes	Dead (unknown)

Cy, cyclophosphamide; Flu, fludarabine; NR, no response; TRM, treatment-related mortality.